Breast cancer: Emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data

Background A growing primary breast cancer (PT) can initiate local (LR), regional (pLN), and distant metastases (MET). Characteristics of these progressions such as initiation, frequency and duration of PT and MET growth describe principles of the MET process. They are bottlenecks through which molecular hypotheses and scientific terms for prediction and prognosis have to go.

Methods Population-based data from the Munich Cancer Registry over 4 time periods since 1978 with the most important prognostic factors and a follow-up up to this day are analyzed. With n= 66.818 patients, reliable data are obtained on initiation on METs, growth times und survival even in small subgroups. Together with results of clinical trials on prevention and adjuvant treatment (AT) principles of tumor growth, MET process and AT are summarized.

Results The median growth periods for PT/ MET/LR/pLN result in 12,5/8,8/5/3,5 years. Even if 30% of METs only appear after 10 years of MET-free time, a delayed initiation or cascade like initiation of METs, e.g. from pLNs cannot be derived from the data. That is an immediate MET initiation principle by PT. The growth rate of the PT can vary by a factor of 10 or more and can be transferred to the MET. The coupling of the growth rates of PT/MET results in the principle of a nearly constant relation of about 1.4. Principles of AT are the 50% eradication of 1st and 2ndPT, the selective and partial eradication of bone and lung METs with successful ATs, which cannot be improved by extending the duration of ATs. These principles reveal that there is no convincing rationale for the currently accepted early risk of breast cancer by hormone replacement therapies, for long term endocrine ATs or cascade like initiation of METs.

Conclusion A paradigm with nine principles for the MET process and ATs can be derived from real world data and clinical trials. The principles suggest alternative interpretations of well-known clinical trials and changes in treatments. The outlined MET process should be generalizable to all solid tumors.